236 related articles for article (PubMed ID: 23540741)
1. Cardiovascular toxicities of cancer chemotherapy.
Bonita R; Pradhan R
Semin Oncol; 2013 Apr; 40(2):156-67. PubMed ID: 23540741
[TBL] [Abstract][Full Text] [Related]
2. Cardiac testing to manage cardiovascular risk in cancer patients.
Davis M; Witteles RM
Semin Oncol; 2013 Apr; 40(2):147-55. PubMed ID: 23540740
[TBL] [Abstract][Full Text] [Related]
3. Detection and prevention of cardiac complications of cancer chemotherapy.
Monsuez JJ
Arch Cardiovasc Dis; 2012 Nov; 105(11):593-604. PubMed ID: 23177488
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
6. [Cardiovascular complications of chemotherapy].
Tovena DM; Inzoli A; Donato G; Gazzaniga P; Bianchessi C
G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):165S-170S. PubMed ID: 23096398
[TBL] [Abstract][Full Text] [Related]
7. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
[TBL] [Abstract][Full Text] [Related]
8. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
9. Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review.
Svoboda M; Poprach A; Dobes S; Kiss I; Vyzula R
Cardiovasc Toxicol; 2012 Sep; 12(3):191-207. PubMed ID: 22528816
[TBL] [Abstract][Full Text] [Related]
10. Brain natriuretic peptide as a cardiotoxicity biomarker in children with hematological malignancies.
Tragiannidis A; Dokos C; Tsotoulidou V; Giannopoulos A; Pana ZD; Papageorgiou T; Karamouzis M; Athanassiadou F
Minerva Pediatr; 2012 Jun; 64(3):307-12. PubMed ID: 22555323
[TBL] [Abstract][Full Text] [Related]
11. [Cardiologic follow up of an oncologic patient].
Zaugg Longchamp D; Zaman K; Aebischer N
Rev Med Suisse; 2010 Jun; 6(251):1133-4, 1136-9. PubMed ID: 20572357
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-related cardiotoxicity.
Aggarwal S; Kamboj J; Arora R
Ther Adv Cardiovasc Dis; 2013 Apr; 7(2):87-98. PubMed ID: 23487044
[TBL] [Abstract][Full Text] [Related]
13. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy.
Oliveira GH; Qattan MY; Al-Kindi S; Park SJ
Circ Heart Fail; 2014 Nov; 7(6):1050-8. PubMed ID: 25415958
[No Abstract] [Full Text] [Related]
14. Heart failure and chemotherapeutic agents.
Piper S; McDonagh T
Future Cardiol; 2015 Jul; 11(4):453-70. PubMed ID: 26234158
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.
Volkova M; Russell R
Curr Cardiol Rev; 2011 Nov; 7(4):214-20. PubMed ID: 22758622
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
Madeddu C; Deidda M; Piras A; Cadeddu C; Demurtas L; Puzzoni M; Piscopo G; Scartozzi M; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e12-e18. PubMed ID: 27755238
[TBL] [Abstract][Full Text] [Related]
17. Cardiac dysfunction in cancer patients receiving paclitaxel.
Valdés Olmos RA; ten Bokkel Huinink WW; Hoefnagel CA
Eur J Nucl Med; 1998 Apr; 25(4):446-7. PubMed ID: 9643974
[No Abstract] [Full Text] [Related]
18. Insights into cardiovascular side-effects of modern anticancer therapeutics.
Stortecky S; Suter TM
Curr Opin Oncol; 2010 Jul; 22(4):312-7. PubMed ID: 20535072
[TBL] [Abstract][Full Text] [Related]
19. Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice.
Goel S; Beith JM
J Clin Oncol; 2011 Mar; 29(7):e175-6. PubMed ID: 21189375
[No Abstract] [Full Text] [Related]
20. [ACE inhibitors in the treatment of ventricular dysfunction caused by cardiotoxic cytostatics].
Mladosievicová B
Ceska Slov Farm; 2004 Mar; 53(2):55-60. PubMed ID: 15095572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
